Europe/London (GMT) time zone

Day 1: 24 June 2022


Opening Session

“Prometheus” basic science key note lecture:
Targeting the ubiquitin proteasome system to fight muscle atrophy: update 2022
Volker Adams, Germany

“Hippocrates” clinical science key note lecture:
From sarcopenia to frailty
John Morley, USA

JCSM & SCWD lecture
Stephan von Haehling, Germany


Coffee Break


A -
Sarcopenia of aging and chronic diseases

Chair: Paola Costelli, Italy

MOTS-c: a new player in aging-related loss of muscle mass and function 
Changhan Lee, USA 

Metabolic and molecular consequences of sarcopenia in alcoholic liver disease
Srinivasan Dasarathy, USA

Bone and muscle crosstalk: Biological and clinical implications
Gustavo Duque, Australia

Results of the SPRINTT trial
Francesco Landi, Italy


B - Clinical Session
Novel aspects of adipose tissue function in wasting

Chairs: Stephan Herzig, Germany, & Mauricio Berriel Diaz, Germany

Immune-sympathetic neuron communication guides adipose tissue browning in cancer-associated cachexia
Martina Schweiger, Austria

Angiocrine signals promote adipose tissue wasting in cancer cachexia
Andreas Fischer, Germany

Brown adipose tissue activation is not related to hypermetabolism in emphysematous COPD patients
Annemie Schols, The Netherlands 

MRI-determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia
Dimitrios Karampinos, Germany


Recent guidelines and consensus developments

Chairs: John Morley, USA, & Andrew Coats, Australia

Appetite is key in geriatric syndromes: a pre-release of SCWD International Guidelines on Anorexia of Aging
Ivan Aprahamian, Brasil

Development of the cachexia consensus in Asia
Hidenori Arai, Japan

Recent guidelines on cancer cachexia: ESPEN, ESMO and ASCO
Alessandro Laviano, Italy


Lunch Session 2


C - 
Recent guidelines and consensus developments

Appetite is key in geriatric syndromes: a pre-release of SCWD International guidelines on anorexia of aging
Ivan Aprahamian, Brazil

Development of the cachexia consensus in Asia
Hidenori Arai, Japan

Recent guidelines on cancer cachexia: ESPEN, ESMO and ASCO
Alessandro Laviano, Italy


D - Clinical Session
Mechanisms of muscle loss due to cancer and chemotherapy and early interventions to help counteract negative effects

Chair: Fabio Penna, Italy

Doxorubicin-induced skeletal muscle atrophy, underlying molecular pathways and potential protective effects of exercise: Evidence from pre-clinical and clinical data
Anouk Hiensch, The Netherlands

Exercise and Nutrition-based Rehabilitation programme (EneRgy) in people with cancer 
Barry Laird, UK

Resistance training during chemotherapy for non-metastatic colon cancer: The FORCE study: Effects on body composition and physical function
Bette Caan, USA

Effects of exercise in patients after curative treatment for esophageal cancer: body composition and adequacy of energy and protein intake (the PERFECT study)
Anne May, The Netherlands


Coffee Break


Poster Session 1


Rapid Fire Abstracts Session 1

10 abstracts – 5 min


E - Basic Science Session
New basic findings in muscle wasting

Chair: Gustavo Nader, USA

Activation of Akt-mTORC1 signaling reverts cancer-dependent muscle wasting
Bert Blaauw, Italy

New insights into the role of GCN2-eIF2alpha signaling in the regulation of autophagy
Anne-Catherine Maurin, France

Interventions for improving mitochondrial function to counteract cancer and chemotherapy-induced cachexia
Fabio Penna, Italy

Fighting muscle loss: lessons from hibernation in brown bear
Etienne Lefai, France


F - Clinical Session
A focus on muscle health: assessment approaches and targeted nutrition interventions

Chair: Stephan von Haehling, Germany

Artificial Intelligence approaches to improve speed, dimensionality and entry into clinical workflows
Faisal Beg, Canada

Surrogate markers of muscle mass and quality
Cristina Gonzalez, Brazil

A mechanistic perspective of specialized nutrition for muscle health
Philip Atherton, UK


Coffee Break


Poster Session 2


Rapid Fire Abstracts Session 2

10 abstracts – 5 min 


G - Basic Science Session
Ammonia and the muscle - multiple diseases, one mechanism

Chair: Annemie Schols, The Netherlands

Mechanisms of ammonia induced sarcopenia – a common mediator in multiple diseases 
Srinivasan Dasarathy, USA

Amino acid perturbations in hyperammonemia 
Milan Holecek, Czech Republic

Multiomics based approaches to identify novel cellular and tissue responses 
Nicole Welch, USA

The significance of myosteatosis in surgical cancer patients
Steven Olde Damink, The Netherlands


H - Clinical Session
Special diets - the power of food

Chair: Wolfram Doehner, Germany

What determines/Which parameters determine optimal protein metabolism in the old?
Dominique Dardevet, France

Manipulating the microbiome to counteract frailty
Patrizia Brigidi, Italy

Nutrition and anorexia of ageing 
Reshma Merchant, Singapore


Day 2: 25 June 2022


J - Clinical Session
Liver alterations as drivers of cancer cachexia

Chairs: Andrea Bonetto, USA, & Andrew Coats, Australia

Hepatic and intestinal disturbances as targets to counteract cancer cachexia 
Laure Bindels, Belgium

A cachexia score based on liver alterations predicts prognosis of gastrointestinal cancer patients
Achim Krüger, Germany

Inflammation and impairment of hepatic metabolism and function in cachectic cancer patients
Marilia Seelaender, Brazil

Liver control of systemic energy metabolism in cancer cachexia
Sören Fisker Schmidt, Denmark


Coffee Break


K - Basic Science Session
Hot topics in basic research: role of muscle stem and progenitor cells during aging, disease and regeneration

Muscle stem cells in age and disease 
Julia von Maltzahn, Germany 

Neurofibromatosis type 1 associated myopathy is due to metabolic reprogramming of muscle stem cells in a mouse model
Sigmar Stricker, Germany 

Fibro-adipogenic progenitors coordinate muscle regeneration 
Georgios Kotsaris, Germany 

Muscle stem cells drive post-sepsis skeletal muscle recovery and regeneration
Jason Doles, USA


L - Clinical Session
Inter-organ crosstalks in cancer cachexia

Chairs: Frank Misselwitz, Germany, & Gustavo Nader, USA

Abnormal liver-bone-muscle axis in cancer cachexia 
Andrea Bonetto, USA

Impact of exercise and chemotherapy on the respiratory neuromuscular system
Ashley Smuder, USA            

Cancer-induced muscle and bone deficits
Hanna Taipaleenmäki, Germany

Cardiac cachexia
Markus Anker, Germany


Coffee Break


Poster Session 3


Rapid Fire Abstracts Session 3

10 abstracts – 5 min


M - Basic Science Session
Cachexia as an heterogeneous disease: underlying mechanisms

Chairs: Jochen Springer, Germany, Marilia Seelaender, Brazil, & Maria Rohm, Germany

Sex-dependent response of adipose tissue and lipid metabolism in cancer cachexia
Vera Mazurak, Canada

Tumor microenvironment evolution and its relevance to cachexia 
Mariam Jamal-Hanjani, UK

Sex variation in cachexia
Silvia Busquets, Spain

Anabolic deficits in muscle wasting: paradigm lost or blind spot? 
Gustavo Nader, USA


N - Clinical Session
State of the art nutrition for outcome driven cancer treatments

Chair: Gustavo Duque, Australia

Integrated evaluation of body composition in the oncology setting: paradigm change 
David da Silva Dias, Portugal

Nutrition options in 2022: What is on the market?
Paula Ravasco, Portugal

Nutrition in ambulatory cytotoxic treatment: New data on the role of the clinical pharmacist
Leila Costa, Portugal

Head and neck cancer and cachexia – a high risk cancer and higher risk treatments 
Maartje van Beers, The Netherlands


Lunchtime Satellite Symposium

Cachexia – Unmet Needs and Opportunities for Novel Therapy

Circulating GDF15 and its relationship with cachexia in non-small cell lung cancer
Mariam Jamal-Hanjani, UK

GDF-15 is a key regulator of cancer cachexia and beyond
Bei Zhang, USA

Questions & Answers

Supported by an educational grant from Pfizer


O - Basic Science Session
Novel cachexia mediators - proteins and beyond

Chairs: Denis Guttridge, USA, Martina Schweiger, Austria, & Stephan von Haehling, Germany

Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia
Tobias Janowitz, USA

Tumor-derived cachexia mediators and biomarkers
Mauricio Berriel Diaz, Germany

Tumor-derived extracellular vesicles 
Paola Costelli, Italy 

KLF10: a novel mediator of cancer-associated skeletal muscle wasting 
Jason Doles, USA


P - Clinical Session
Cancer progression and cachexia


Exercise and tumor control: expanding the field of exercise oncology to cancer progression and cachexia
Lee Jones, USA

Cardiac wasting in cancer
Alessia Lena, Germany

A review of the evidence for multi-modal interventions in cachexia management
Joanne Reid, UK

ACTAs for cancer cachexia
Andrew Coats, Australia


Coffee Break


Poster Session 4


Q - Basic Science Session
Mechanisms of energy and anabolic crisis in cancer cachexia – new therapeutic targets?

MyomiRNA, systemic and local inflammation and muscle wasting 
Maurizio Muscaritoli, Italy

The transcriptional repressor FoxP1 in cancer-induced skeletal muscle wasting and weakness
Sarah Judge, USA

Beyond good and evil: Discovering novel anabolic targets to overcome cancer related-muscle wasting
Marcelo Pereira, UK

Skeletal muscle mitochondrial dysfunction and lipid accumulation in breast cancer 
Emidio Pistilli, USA


R - Clinical Session
Designing trials for cancer cachexia

Chairs: Teresa Zimmers, USA, & Andrew Coats, Australia

Definition of cancer cachexia and measuring muscle mass in clinical trials 
Vickie Baracos, Canada

Endpoints for cancer cachexia clinical trials 
Stefan Anker, Germany

Use of biomarkers to assess treatment effect in cancer cachexia 
Jose Garcia, USA

Regulatory perspective on Cancer Cachexia Trials 
Giuseppe Rosano, UK


Coffee Break


S - Basic Science Session
Cachexia & muscle wasting – pathophysiology update

Chairs: Marco Sandri, Italy, Jason Doles, USA, & Denis Guttridge, USA

T cells and cachexia
Laura Antonio-Herrera, Austria

NMJ defects and stem cell defects in wasting muscle
Joe Chakkalakal, USA

Macrophages and muscle regeneration
Emanuele Berardi, Belgium

Endothelial dysfunction in cachexia
Young-Mee Kim, USA


Y1 - Young Investigators Award Session


Coffee Break


U - Basic Science Session
Host-specific and tumor-specific molecular mechanisms of biological variability in cancer cachexia

Chairs: Mauricio Berriel Diaz, Germany, & Puneeth Iyengar, USA

Host factors: sexual dimorphism in murine models of cancer cachexia
Nicholas Greene, USA

Host factors: aging and host genotype in cancer cachexia
Maria Rohm, Germany

Tumor factors: tumor molecular and cellular heterogeneity mediates cancer cachexia phenotype
Teresa Zimmers, USA

In vivo screening reveals lung cancer tumor-specific mediators of cancer cachexia in mice
Rodney Infante, USA


V - Clinical Session
Cachexia in chronic kidney disease: recent advances

Impact of protein intake on CKD cachexia and sarcopenia 
Kam Kalantar-Zadeh, USA                  

Physical activity and nutrition in CKD  
Angela Wang, Hong Kong

Inflammation and adipose tissue browning in CKD cachexia  
Robert Mak, USA 

Activin signaling and GDF-15 in CKD cachexia 
Connie Rhee, USA

Day 3: 26 June 2022


Covid-19 and cachexia: common players and perspectives

Chairs: Mauricio Muscaritoli, Italy, Annemie Schols, The Netherlands, & Mitja Lainscak, Slovenia

The role of adipose tissue in Covid-19 cytokine storm: learning from cachexia 
Marilia Seelaender, Brazil

Nutrition: a matter of life or death  
Alessandro Laviano, Italy

Body composition and muscle quality in Covid-19 patients 
Martine Sealy, The Netherlands

Frailty and rehabilitation in Covid-19 patients 
Francesco Landi, Italy




Multi-modal interventions for cachexia

Chair: Joanne Reid, UK

Evolution and outcomes from a multi-disciplinary cachexia clinic
Peter Martin, Australia 

Clarifying the role of palliative rehabilitation in cachexia management
Cathy Payne, Belgium

The importance of exercise and nutrition in an integrated response to cachexia management 
Adrian Slee, UK

Patient experience of a multi-professional cachexia clinic
Vanessa Vaughan, Australia




Mechanisms of cancer cachexia – transition from basic research to clinical investigation

Chair: Teresa Zimmers, USA

MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer
Andrew R. Judge, USA 

Activation of p38β MAPK in skeletal muscle correlates with weight loss in cancer patients 
Yi-Ping Li, USA

Association between growth differentiation factor-15 (GDF-15) serum levels, anorexia and low muscle mass among cancer patients
Alessio Molfino, Italy

Adipose depot gene expression and intelectin-1 in the metabolic response to cancer and cachexia
Richard J. E. Skipworth, UK


Lunch Session 5


Late Breaking Trials Session




Targeting cachexia treatment: GDF15 and beyond

Chair: Maurizio Muscaritoli, Italy

GDF15 neutralization as a transformative therapeutic approach
Bei Zhang, Pfizer, USA

Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15  
Danna Breen, USA

MC4R antagonism for appetite and body weight regulation – from human genetics to aged rat model
Zhidan Wu, USA


Highlights Session

Consent Management Platform by Real Cookie Banner